机构：[1]School of Medicine and Centre for Molecular and Medical Research, Deakin University, 75 Pigdons Road, Waurn Ponds, Victoria 3216, Australia[2]CSIRO Australian Animal Health Laboratory, Private Bag 24, Geelong, Victoria 3220, Australia[3]Centre for Chemistry and Biotechnology, School of Life and Environmental Sciences, Faculty of Science, Engineering and Built Environment, Deakin University, Waurn Ponds, Victoria 3216, Australia[4]School of Nursing, Zhengzhou University, 100 Kexue Ave, Zhengzhou, P. R. China, 450001[5]Centre for Comparative Genomics, Murdoch University, 90 South Street, Murdoch, WA 6150, Australia[6]Suzhou GenePharma, 199 Dongping Street, Suzhou 215123, P. R. China[7]Cancer Care Centre, St George Hospital and St George and Suthland Clinical School, University of New South Wales (UNSW), High Street, Kensington, NSW 2052, Australia[8]Deakin University, Australia, Institute for Frontier Materials, 75 Pigdons Road, Waurn Ponds, Victoria, 3216[9]College of Life Sciences, Sichuan University, No.24 South Section 1, Yihuan Road, Chengdu 610041, P. R. China[10]Department of Bioengineering and Biotechnology, College of Chemical Engineering, Huaqiao University, 668 Jimei Avenue, Xiamen, Fujian 361021, P. R. China[11]Center for Qinba Region's Sustainable Development, Shaanxi Normal University, No.199, South Chang’an Road, Xi'an, Shaanxi 710062, P. R. China[12]Department of Oncology, Affiliated Sixth People’s Hospital, Shanghai Jiaotong University, No. 600, Yishan Road, Shanghai 200233, P. R. China.
Chemotherapy-resistant cancer stem cells (CSCs) are a major obstacle to the effective treatment of many forms of cancer. To overcome CSC chemo-resistance, we developed a novel system by conjugating a CSC-targeting EpCAM aptamer with doxorubicin (Apt-DOX) to eliminate CSCs. Incubation of Apt-DOX with colorectal cancer cells resulted in high concentration and prolonged retention of DOX in the nuclei. Treatment of tumour-bearing xenograft mice with Apt-DOX resulted in at least 3-fold more inhibition of tumour growth and longer survival as well as a 30-fold lower frequency of CSC and a prolonged longer tumourigenic latency compared with those receiving the same dose of free DOX. Our data demonstrate that a CSC-targeting aptamer is able to transform a conventional chemotherapeutic agent into a CSC-killer to overcome drug resistance in solid tumours.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|1 区医学
小类|1 区医学：研究与实验
最新[2023]版：
大类|1 区医学
小类|1 区医学：研究与实验
第一作者：
第一作者机构：[1]School of Medicine and Centre for Molecular and Medical Research, Deakin University, 75 Pigdons Road, Waurn Ponds, Victoria 3216, Australia
通讯作者：
通讯机构：[1]School of Medicine and Centre for Molecular and Medical Research, Deakin University, 75 Pigdons Road, Waurn Ponds, Victoria 3216, Australia[12]Department of Oncology, Affiliated Sixth People’s Hospital, Shanghai Jiaotong University, No. 600, Yishan Road, Shanghai 200233, P. R. China.[*1]Department of Oncology, Affiliated Sixth People’s Hospital, Shanghai Jiaotong University, No. 600, Yishan Road, Shanghai 200233, P. R. China[*2]School of Medicine, Deakin University, 75 Pigdons Road, Waurn Ponds, Victoria, 3217, Australia.
推荐引用方式(GB/T 7714)：
Dongxi Xiang,Sarah Shigdar,Andrew G Bean,et al.Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery.[J].Theranostics.2017,7(17):4071-4086.doi:10.7150/thno.20168.
APA：
Dongxi Xiang,Sarah Shigdar,Andrew G Bean,Matthew Bruce,Wenrong Yang...&Wei Duan.(2017).Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery..Theranostics,7,(17)
MLA：
Dongxi Xiang,et al."Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery.".Theranostics 7..17(2017):4071-4086
医学